Design of viral surface antigen-HSP fusion protein to modulate nasal mural immunity
Noninvasive vaccines targeting nasopharynx-associated lymphoid tissue (NALT) have potential for the next generation of vaccines. Here, we attempted to synthesize a fusion protein with the viral surface antigen by utilizing HSP as a candidate adjuvant targeting Microfold (M) cells.